.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,458,764

« Back to Dashboard

Details for Patent: 6,458,764

Title: GRF analogs with increased biological potency
Abstract:The present invention relates to chimeric fatty body-GRF analogs with increased biological potency, their application as anabolic agents and in the diagnosis and treatment of growth hormone deficiencies. The chimeric fatty body-GRF analogs include an hydrophobic moiety (tail), and can be prepared, either by anchoring at least one hydrophobic tail to the GRF, in the chemical synthesis of GRF. The GRF analogs of the present invention are biodegradable, non-immunogenic and exhibit an improved anabolic potency with a reduced dosage and prolonged activity.
Inventor(s): Gravel; Denis (St-Lambert, CA), Habi; Abdelkrim (Anjou, CA), Brazeau; Paul (Montreal, CA)
Assignee: Theratechnologies Inc. (Montreal, CA)
Filing Date:Sep 03, 1999
Application Number:09/389,486
Claims:1. An hydrophobic GRF analog of formula A:

wherein; the GRP peptide is a peptide of formula B;

wherein, A1 is Tyr or His; A2 is Val or Ala; A8 is Asn or Ser; A13 is Val or Ile; A15 is Ala or Gly; A18 is Ser or Tyr; A24 is Gln or His; A25 is Asp or Glu; A27 is Met, Ile or Nle; A28 is Ser or Asn; A30 is a bond or any amino acid sequence of 1 up to 15 residues; R.sub.0 is NH.sub.2 or NH-(CH.sub.2)n-CONH.sub.2, with n=1 to 12 and;

X is a hydrophobic tail anchored via an amide bond to the N-terminus of the peptide and said hydrophobic tail defining a backbone of 5 to 7 atoms; wherein said backbone can be substituted by C.sub.1-6 alkyl, C.sub.3-6 cycloalkyl, or C.sub.6-12 aryl; and comprises at least one rigidifying moiety connected to at least two atoms of the backbone; said moiety selected from the group consisting of double bond, triple bond, saturated or unsaturated C.sub.3-9 cycloalkyl, and C.sub.6-12 aryl

and wherein X is selected from the group consisting of: ##STR22## ##STR23##

2. A pharmaceutical formulation for inducing growth hormone release which comprises as an active ingredient a GRF analog as claimed in claim 1, in association with a pharmaceutically acceptable carrier, excipient or diluent.

3. A method of increasing the level of growth hormone in a patient which comprises administering to said patient an effective amount of a GRF analog as claimed in claim 1.

4. A method for the diagnosis of growth hormone deficiencies in patients, which comprises administering to said patient a GRF analog as claimed in claim 1 and measuring the growth hormone response.

5. A method for the treatment of pituitary dwarfism or growth retardation in a patient, which comprises administering to said patient an effective amount of a GRF analog as claimed in claim 1.

6. A method for the treatment of wound or bone healing in a patient, which comprises administering to said patient an effective amount of a GRF analog as claimed in claim 1.

7. A method for the treatment of osteoporosis in a patient, which comprises administering to said patient an effective amount of a GRF analog as claimed in claim 1.

8. A method for improving protein anabolism in human or animal, which comprises administering to said human or animal an effective amount of a GRF analog as claimed in claim 1.

9. A method for inducing a lipolytic effect in human or animal inflicted with clinical obesity, which comprises administering to said human or animal an effective amount of a GRF analog as claimed in claim 1.

10. A method for the overall upgrading of somatroph function in human or animal, which comprises administering to said human or animal an effective amount of GRF analog as claimed in claim 1.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc